Objective: Transcatheter heart valve implantation in failed aortic bioprostheses (valve-in-valve [ViV]) is an increasingly used therapeutic option for high-risk patients. However, high postprocedural gradients are a significant limitation of aortic ViV. Our objective was to evaluate Medtronic CoreValve Evolut R ViV hemodynamics in relation to the degree of device oversizing and depth of implantation.
ViV procedures in May 2013, and the Edwards SAPIEN XT valve received CE mark in early 2014. In addition, the US Food and Drug Administration (FDA) approved both THVs for aortic ViV procedures in the United States in 2015. There is growing clinical experience and technical refinement with the transcatheter treatment of failed surgical bioprostheses. [3] [4] [5] [6] Thus far, the main adverse outcomes of ViV implantations observed in clinical trials and studies have been device malposition, coronary obstruction, and elevated postprocedural gradients. 3, [7] [8] [9] [10] [11] THV malposition and coronary obstruction are becoming less common due to a better understanding of the fluoroscopic landmarks of surgical bioprostheses, and optimal screening and technical proficiency to prevent coronary obstruction. 12, 13 However, the main limitation of THV implantation in degenerated stented surgical bioprostheses is residual stenosis, which is associated with poor clinical outcomes [7] [8] [9] and possibly limited THV long-term durability. 14 In stented surgical bioprosthetic valves, the rigid annulus of the sewing ring, and to some extent stent posts, can constrain an oversized THV and prevent full expansion of the frame. 15, 16 Lack of expansion can result in elevated postprocedural gradients, distorted THV leaflet shape, and possibly prosthetic-patient mismatch. 3, 17, 18 Current sizing guidelines and recommendations are normally based on the true internal diameter of stented surgical bioprostheses. 12 These use in vitro measured benchmarks, algorithms, or computed tomography measurement to adjust for the leaflet material inside of the stent. However, there are discrepancies and contradictions between THV sizing guidance and potential hemodynamic benefits. For example, the ViV app, VIV(AORTIC) (Mr Vinayak Bapat and UBQO, London, United Kingdom), commonly used in clinical practice, recommends the 23-mm CoreValve for ViV implantation in Hancock II up to the label size of 25 mm. However, in general, a larger THV device has a larger intrinsic leaflet geometric orifice area and may possibly splay the surgical valve posts better. Excessive THV oversizing may lead to increased leaflet distortion, which may in turn lead to poor device durability. 14 On the other hand, evidence suggests that supra-annular deployment of THVs is associated with lower gradients and superior hemodynamics after ViV implantations. [19] [20] [21] Excessively high implantation of the commercially available THVs could increase the risk of valvular regurgitation, device malposition, and coronary occlusion or stenosis. As such, it is necessary to determine the appropriate THV size and sweet spot for implantation of the commercially available THV devices in ViV procedures. This in vitro study aims to better understand CoreValve Evolut R hemodynamics in relation to degree of THV oversizing and deployment location.
MATERIALS AND METHODS THVs and ViV Deployment
The 23-mm and 26-mm CoreValve Evolut R devices were implanted within nondegenerated, 21-, 23-, and 25-mm Hancock II bioprostheses (Medtronic). The 23-mm Evolut R has a maximum outflow diameter of 34 mm and a minimum waist diameter of 20 mm. The 26-mm Evolut R has a maximum outflow diameter of 32 mm and a minimum waist diameter of 22 mm. For both devices, the frame height without paddles is 45 mm and the skirt height is 13 mm. In addition, the true internal diameter of the stented bioprostheses were 16.5, 18.5, and 20.5 mm, respectively, exactly 2 mm less than the stent (frame) internal diameters holding the leaflets in place. Furthermore, the height of 21-, 23-, and 25-mm Hancock II bioprostheses were 15, 16, and 17.5 mm, respectively. Small and gradual changes in implantation depth were attempted. Each position was assessed by radiographic imaging for its implantation depth before in vitro hemodynamic testing (Figure 1 ). For the determination of implantation depth, the bottom diamond of the CoreValve Evolut R devices was used as the reference for a scale. One straight line, starting at the surgical valve ring, was traced on each side of the device. The 2 values obtained were added together and their average was considered the final depth of implantation for each case. Subsequently, in vitro bench testing was performed with multiple implantation depths of the 2 THV devices. In this study, only 1 valve was tested in each implantation depth due to the high cost of the clinicalgrade THVs.
In Vitro Hemodynamic Measurements
THVs were tested at 37 C in a custom-built pulse duplicator system. Heart rate, blood pressure, and cardiac output were used as control parameters for the waveform generator controlling a servo pump. Normal saline solution was used as recirculating fluid for the hemodynamic measurements. Transvalvular pressure measurements were obtained with 2 pressure transducers (Deltran; Utah Medical Products, Inc, Midvale, Utah) embedded inside an optically clear tube 25 mm downstream and 75 mm upstream of the bioprostheses. The internal diameter of the tube upstream and downstream of the bioprostheses was 1 inch and 2 inches, respectively. Furthermore, an electromagnetic flowmeter (CME 500 Series; Carolina Medical Electronics, Inc, East Bend, NC) was used to measure aortic valve flow rate. Pulse duplicator input parameters were used to match ISO 5840 standard and FDA specifications for testing heart valves: heart rate of 70 beats per minute, 35% systolic duration of cycle period, mean atrial and aortic pressures of 10 and 100 mm Hg, and cardiac output 5 L/min. The hemodynamic parameters were maintained constant throughout the study. Valvular mean pressure gradient, effective orifice area (EOA), and regurgitation fractions were measured. EOA was calculated based on the Gorlin equation. In addition to the hemodynamic testing, short-axis images of the opening and closing of the devices were recorded by a Photron highspeed camera (FASTCAM SA4; Photron USA, Inc, San Diego, Calif) during the entire cardiac cycle at a rate of 1000 frames per second.
Statistical Analysis
All statistical analyses were performed in SPSS 16.0 (IBM SPSS Inc, IBM Corporation, Chicago, Ill). The acquired data were averaged over 10 cardiac cycles to achieve the mean and standard deviation. A P value less than .05 was regarded as statistically significant. Shapiro-Wilk test of normality with an alpha level of 0.05 was performed to ensure normal
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EOA ¼ effective orifice area THV ¼ transcatheter heart valve ViV ¼ valve-in-valve distribution of the data. Unpaired t test was used to compare values between groups. In addition, polynomial regression (linear and quadratic) was performed for each THV device, with 3 correlations performed: implantation depth and mean pressure gradient, implantation depth and EOA, and implantation depth and regurgitation volume. In addition, analysis of variance was used to assess the fit of the data to linear and quadratic equations. Moreover, 95% confidence bands for regression curves were obtained and reported.
RESULTS

ViV Results in 21-mm Hancock II Bioprostheses
Thirteen in vitro experiments were performed using 23-mm CoreValve Evolut R in 21-mm Hancock II bioprostheses at varied implantation depths from À3.8 mm to 14.6 mm. Furthermore, 9 hemodynamic tests were performed using 26-mm CoreValve Evolut R in 21-mm Hancock II bioprostheses at implantation depths ranging from À0.7 mm to 12.7 mm. 
ViV Results in 23-mm Hancock II Bioprostheses
Seven in vitro experiments were performed using 23-mm CoreValve Evolut R in 23-mm Hancock II bioprostheses at varied implantation depths from À0.5 mm to 10.0 mm. Furthermore, 10 hemodynamic tests were performed using the 26-mm CoreValve Evolut R in the 23-mm Hancock II bioprostheses at implantation depths ranging from À0.6 mm to 10.4 mm. 18.00 AE 0.26 mm Hg. Quadratic regression demonstrated a correlation between higher implantation and lower mean gradients (P ¼ .031).
In addition, the EOA of the 23-mm THV was between 1.45 AE 0.01 cm 2 and 1.64 AE 0.01 cm 2 . Although the trend was not statistically significant (P ¼ .325), quadratic regression of EOA demonstrated an increasing trend with higher implantation depths. On the other hand, the mean transvalvular pressure gradient of the 26-mm CoreValve Evolut R was lower than the 23-mm CoreValve Evolut R, ranging from 11.90 AE 0.15 mm Hg to 15.80 AE 0.22 mm Hg (Figure 3) . Quadratic regression demonstrated a correlation between higher implantation and lower mean gradients (P ¼ .049). In addition, the EOA of the 26-mm THV was between 1.63 AE 0.01 cm 2 than ViV implantation using the 23-mm CoreValve Evolut R. Furthermore, quadratic regression demonstrated a correlation between higher implantation and higher EOA (P < .001). Additionally, visual evaluation showed that the oversized THVs were constrained by the rigid bioprostheses resulting in leaflet distortion, particularly at lower implantation depths ( than the 23-mm CoreValve Evolut R, ranging from 10.60 AE 0.17 mm Hg at 0.7-mm depth of implantation to 11.70 AE 0.14 mm Hg at 8.6-mm depth of implantation ( Figure 4) . Linear regression demonstrated a correlation between higher implantation and lower mean gradients (P ¼ .028). In addition, the EOA of the 26-mm THV was between 1.82 AE 0.01 cm 2 and 2.00 AE 0.01 cm 2 , significantly higher than ViV implantation using the 23-mm CoreValve Evolut R. Furthermore, linear regression demonstrated a correlation between higher implantation and higher EOA (P ¼ .043). In addition, visual evaluation showed that the oversized THVs were constrained by the rigid bioprostheses, resulting in leaflet distortion, particularly at lower implantation depths (Figure 4 , B and D; Videos 9 and 11). However, better leaflet coaptation was visually evident in higher implanted cases (Figure 4 , A and C; Videos 10 and 12). Figure 5 summarizes the mean pressure gradient of 23-mm and 26-mm CoreValve Evolut R devices within 21-, 23-, and 25-mm Hancock II bioprostheses. As expected, lower mean transvalvular pressure gradients were obtained after ViV within larger-size surgical bioprostheses using the 23-mm and 26-mm CoreValve Evolut R. In addition, there was a correlation between higher implantation and lower mean transvalvular gradient for all the cases except the 23-mm CoreValve Evolut R in 25-mm Hancock II bioprostheses. As presented in Figure 5 , left, the internal characteristics of the 23-mm CoreValve Evolut R were not interfered with by the surgical bioprostheses close to zero depth positions and comparable values of mean gradient were obtained after ViV in the 21-, 23-, and 25-mm Hancock II bioprostheses. Moreover, the 26-mm CoreValve Evolut R had superior hemodynamics to the 23-mm CoreValve Evolut R in both 23-mm and 25-mm Hancock II bioprostheses (P < .001). However, the hemodynamic results of the 26-mm CoreValve Evolut R in 21-mm Hancock II bioprostheses were worse than the 23-mm CoreValve Evolut R, even in the high positions (P<.001). As shown in Figure 6 , regardless of implantation depth, a superior transvalvular pressure gradient is expected with the 26-mm Evolut R than the 23-mm Evolut R in 
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DISCUSSION
Transcatheter aortic ViV is a safer alternative to redo surgical valve replacement in managing degenerated bioprostheses. Currently, the major limitation of ViV implantation in degenerated stented surgical bioprostheses is residual stenosis, which is associated with poor clinical outcomes. [7] [8] [9] In the current analysis, we aimed to evaluate for techniques that may improve hemodynamics after ViV, while using the most common THV device currently used in the aortic position: CoreValve Evolut R. Our results suggest that supra-annular implantation of 23-mm and 26-mm Evolut R devices within the bioprostheses can lead to lower gradient, higher EOA, and improved leaflet coaptation after ViV implantation. Furthermore, discordant to conventional recommendations, the 26-mm CoreValve Evolut R had hemodynamics superior to the 23-mm CoreValve Evolut R in 23-mm and 25-mm Hancock II bioprostheses, but not in the 21-mm Hancock II. Regardless of implantation depth, superior transvalvular gradient is expected with the 26-mm Evolut R than the 23-mm Evolut R in a nonstenotic Hancock II with a true internal diameter>17.5 mm.
There are very few technical measures that could be taken while doing ViV cases. During the procedure, the operator can use a certain THV size and aim for a certain implantation depth. Although in the past few years several clinical and bench-testing articles suggested that high implantation is beneficial, there is virtually no knowledge on the size of THV and ability to achieve better hemodynamics in ViV. A natural concern is that a larger THV device would result in more underexpansion and worse hemodynamics. On the other hand, a larger device has a larger intrinsic leaflet orifice area and may splay the surgical valve posts better. Therefore, there should be a balance between different concerns related to this aspect. This is especially true when the surgical valve ring protects from annular injury and therefore issues related to aggressive oversizing may not be similar in ViV procedures in comparison with native aortic valve transcatheter aortic valve replacement procedures. The dilemma regarding the size of THV device in ViV procedures is especially viable, as many different charts and the widely used ViV application consider using the smaller THV size in most clinical cases, such as the 23-mm CoreValve Evolut R. If indeed, according to the current analysis, better hemodynamics may be achieved with a larger THV device, such as 26-mm CoreValve Evolut R, that may decrease the risk of having a prosthetic-patient mismatch in some of these ViV cases and improve device durability.
In the current in vitro analysis, we determined hemodynamic outcomes of 23-mm and 26-mm CoreValve Evolut R devices within 21-, 23-, and 25-mm Hancock II bioprostheses. Mean transvalvular pressure gradient of the 26-mm CoreValve Evolut R in the 23-mm and 25-mm Hancock II was lower than the 23-mm CoreValve Evolut R (P <.001). Furthermore, our results suggest that supra-annular implantation of 23-mm and 26-mm CoreValve Evolut R devices within the surgical bioprostheses can lead to lower gradients and higher EOAs after ViV implantation. Visual evaluation of the THVs also showed improved leaflet coaptation and movement in high-implanted devices. Note that assessment of valve performance based on valvular energy loss allows assessment of prosthetic valve performance during the entire cardiac cycle (during forward and regurgitant flow all together), as shown previously. 22 The total valvular energy loss of ViV cases examined in this study is presented in the supplementary materials (Figures E1 and E2) . Because normal saline solution used in the experimental testing does not have any coagulation properties, regurgitation is expected to be greater in our in vitro experiments than clinical observations. As a result, higher valvular energy loss is expected during diastole in the in vitro testing than in vivo. The results of this study suggest that optimal THV size and VIV deployment positions exist for CoreValve Evolut R devices in Hancock II surgical bioprostheses; superior transvalvular gradient is expected with the 26-mm Evolut R than the 23-mm Evolut R in Hancock II with a true internal diameter >17.5 mm regardless of implantation depth ( Figure 6 ). The true internal diameter of surgical bioprostheses varies based on manufacturer, model, and size, as listed in Table 1 . Based on the results of the present study, further investigation is motivated to determine ViV hemodynamics of 23-mm and 26-mm CoreValve Evolut R devices in the other surgical bioprosthesis to determine the optimal THV size and deployment position. Current sizing guidelines and recommendations are normally based on the true internal diameter of stented surgical bioprostheses. 12 The ViV aortic app recommends 23-mm CoreValve for ViV implantation in the 25-mm Hancock II, but the THV manufacturer's instructions for use recommends the 26-mm CoreValve in the 25-mm Hancock II bioprosthesis. For the 23-mm Hancock II, both the ViVaortic application and the THV manufacturer's instructions recommend the 23-mm CoreValve. On the other hand, no specific guideline is available for the 21-mm Hancock II in both the ViV aortic application and the THV manufacturer's instructions. Therefore, the current sizing guidelines and recommendations retain conflicting details, and there are no specific documented recommendations for a number of small surgical bioprostheses. Furthermore, there are considerable design differences among the commercially available THVs and surgical bioprostheses. As a result, extensive in vitro testing according to ISO-5840 standard and FDA specifications is required to truly evaluate ViV hemodynamic performance based on THV type, size, and deployment position in different surgical bioprostheses, and develop hemodynamics-based guidelines for transcatheter ViV in degenerated surgical bioprostheses.
In addition, as shown in this study, although the mean transvalvular pressure gradient of the 26-mm CoreValve Evolut R in 23-mm and 25-mm Hancock II was lower than the 23-mm CoreValve Evolut R, visual evaluation of the 26-mm Evolut R showed increased leaflet distortion particularly at lower implantation depths. Based on the ISO-5840 standard, localized bending of THV leaflets should be avoided due to potential for premature tissue degradation. A recent article by Abbasi et al 14 demonstrated that incomplete deployment of a THV induced localized high-stress regions within the THV leaflets. Increased mechanical stress on THV leaflets may lead to accelerated failure of the bioprosthetic leaflets and diminished long-term valve durability. [23] [24] [25] [26] [27] [28] [29] Therefore, although the mean gradient of the 26-mm CoreValve Evolut R in the 23-mm and 25-mm Hancock II was lower than the 23-mm CoreValve Evolut R, long-term results of structural valve degeneration of the larger THV device with increased leaflet distortion may possibly be related to poor device durability. Nevertheless, the long-term durability of THV devices in the ViV setting is currently unknown, and long-term clinical assessment is required to answer this question.
Although the CoreValve Evolut R's leaflets are already in a supra-annular position, supra-annular implantation of the Evolut R resulted in a more complete expansion of the distal portion of the THVs. Nevertheless, supra-annular positioning of the CoreValve Evolut R may lead to increased regurgitation during diastole. The lowest leakage was observed at conventional CoreValve Evolut R ViV position (approximately 6 to 8 mm depth of implantation). Furthermore, significant subannular positioning of CoreValve Evolut R may lead to increased aortic regurgitation. Although the regurgitation for all the ViV cases reported in this in vitro study would be classified as mild regurgitation, higher regurgitation volumes may occur in patients with degenerated surgical valves due to specific functional anatomy and characteristics of the calcified surgical bioprostheses.
Study Limitations
The present study was limited to testing in vitro conditions. In addition, in the current study, we have considered only a specific stented surgical bioprosthesis for ViV using the CoreValve Evolut R. Although this is probably the most common THV device now used, extrapolating current findings to other stentless/stented surgical bioprostheses or ViV using other types of THV devices should be made cautiously. Furthermore, the bioprosthetic valves that were used in our experiments were not degenerated. THV implantation within a degenerated bioprosthesis could be more complicated due to stent deformation, leaflet calcification, or pannus. The data presented in this study could reflect results from leaflet tearing in surgical valves without concomitant calcification. Nevertheless, the importance of THV size and depth of implantation on VIV hemodynamics were already analyzed in cases included in the Valve-in-Valve International Data Registry, with similar findings that validate the importance of the findings revealed in the current analysis in clinical cases. 30 Nevertheless, the current in vitro study should be considered as more important for testing the significance of THV size and depth implantation, as the bench testing was performed in a well-controlled and consistent environment. This could never be performed while assessing real-world in vivo clinical cases, which differ in their leftventricular ejection fraction, aortic and left-ventricular pressures, and in many other aspects. Moreover, based on the ISO-5840 guideline, hemodynamic testing can be performed using a test fluid of isotonic saline, blood, or a bloodequivalent fluid whose physical properties are appropriate to the test being performed. In this study, normal saline solution was used as recirculating fluid. Using blood or a bloodequivalent fluid can lead to slightly higher transvalvular pressure gradients due to increased viscous forces within the flow field. Finally, it should be noted that the implant depths explored in this study fall outside of the manufacture's recommendations for implant depth, whereas some sizing (eg, 26 CoreValve Evolut R to an annulus<20 mm) falls outside of the CoreValve Evolut R's instructions for use.
CONCLUSIONS
The current comprehensive bench-testing assessment demonstrates the importance of both THV size and high device position for the attainment of optimal hemodynamics during ViV procedures. Our results suggest that supraannular implantation of Evolut R devices within the bioprostheses can lead to lower gradient and improved leaflet coaptation. Regardless of implantation depth, superior transvalvular gradient is expected with the 26-mm Evolut R than the 23-mm Evolut R in a nonstenotic Hancock II with a true internal diameter >17.5 mm. Additional in vitro testing may further evaluate ViV hemodynamic performance based on THV type, size, and deployment position in different surgical bioprostheses and develop hemodynamics-based guidelines for the transcatheter ViV procedure. Clinicians must carefully weigh the benefit of using larger THV devices and supra-annular THV implantation in reducing postprocedural gradients against the potential risk for coronary obstruction and THV leaflet distortion in potential ViV candidates.
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